VirtualToxLab - A platform for estimating the toxic potential of drugs, chemicals and natural products

Toxicology and Applied Pharmacology

Volumn 261, Issue 2, 2012, Pages 142-153

  Vedani, Angelo ^a,b   Dobler, Max ^a   Smieško, Martin ^b  

^a Biographics Laboratory 3R   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Automated, flexible docking; In silico toxicology; Multi dimensional QSAR; Open access platform; Toxicity alerts; VirtualToxLab

Indexed keywords

ADENINE; ADRENALIN; ALCOHOL; ANDROGEN RECEPTOR; AROMATIC HYDROCARBON RECEPTOR; ASCORBIC ACID; ATROPINE; CITRIC ACID; CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; ENDOCRINE DISRUPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GLUCOCORTICOID RECEPTOR; LIMONENE; LIVER X RECEPTOR; MIBEFRADIL; MINERALOCORTICOID RECEPTOR; NATURAL PRODUCT; NICOTINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; POTASSIUM CHANNEL HERG; PROGESTERONE RECEPTOR; RISPERIDONE; SALMETEROL; SILDENAFIL; TEGASEROD; VARDENAFIL;

ARTICLE; COMPUTER PROGRAM; HYDROGEN BOND; MOLECULAR DOCKING; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RECEPTOR BINDING; VIRTUALTOXLAB;

BIOLOGICAL AGENTS; DRUG TOXICITY; ENDOCRINE DISRUPTORS; MODELS, MOLECULAR; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SOFTWARE; THERMODYNAMICS; TOXICITY TESTS;

EID: 84860999989     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2012.03.018     Document Type: Article

References (64)

1. Amini A., Mugleton S.H., Lohdi H., Sternberg M.J.E. A novel logic-based approach for quantitative toxicology prediction. J. Chem. Inf. Model. 2007, 47:998-1006.
2. Aronov M.A., Balakin K.V., Kiselyov A., Varma-O'Brien S., Ekins S. Application of QSAR to ion channels. Computational Toxicology - Risk Assessment for Pharmaceutical and Environmental Chemicals 2007, 353-390. J. Wiley & Sons, New York, NY, USA. S. Ekins (Ed.).
3. Aronov A.M. Predictive in silico models for hERG channel blockers. Drug Discovery Today 2005, 10:149-155.
4. Bars R., Broeckaert F., Fegert I., Gross M., Hallmark N., Kedwards T., Lewis D., O'Hagan S., Panter G.H., Weltje L., Weyers A., Wheeler J.R., Galay-Burgos M. Science based guidance for the assessment of endocrine-disrupting properties of chemicals. Reg. Toxicol. Pharmacol. 2011, 59:37-46.
5. Bender A., Scheiber J., Glick M., Davies J.W., Azzaoui K., Hamon J., Urban L., Whitebread S., Jenkins J.L. Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure. ChemMedChem 2007, 2:861-873.
6. Benfenati E., Begnini R., DeMarini D.M., Helma C., Kirkland D., Martin T.M., Mazzatorta P., Quedraogo-Arras G., Richard A.M., Schilter B., Schoonen W.G., Snyder R.D., Yang C. Predictive models for carcinogenicity and mutagenicity: frameworks, state-of-the-art, and perspectives. J. Environ. Sci. Health C Environ. Carcinog. Ecotoxicol. Rev. 2009, 27:57-90.
7. Bowers J.L., Tyulmenkov V.V., Jernigan S.C., Klinge C.M. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors α and β. Endocrinonlogy 2000, 141:3657-3667.
8. Bowers K.J., Chow E., Xu H., Dror R.O., Eastwood M.P., Gregersen B.A., Klepeis J.L., Kolossváry I., Moraes M.A., Sacerdoti F.D., Salmon J.K., Shan Y., Shaw D.E. Proceedings of the 2006 ACM/IEEE Conference on Supercomputing Table of Contents. Tampa, Florida 2006.
9. Colborn T., vom Saal F.S., Soto A.M. Developmental effects of endocrine-disrupting chemicals in wildlife and humans. Environ. Heal. Perspect. 1993, 101:378-384.
10. Crivori P., Poggesi I. Computational approaches for predicting CYP-related metabolism properties in the screening of new drugs. Eur. J. Med. Chem. 2006, 41:795-808.
11. Custer L.L., Kreatsoulas C., Durham S.K. Predicitve mutagenicity computer models. Computational Toxicology - Risk Assessment for Pharmaceutical and Environmental Chemicals 2007, 391-402. J. Wiley & Sons, New York, NY, USA. S. Ekins (Ed.).
12. Cronin M.T., Dearden J.C., Walker J.D., Worth A.P. Quantitative structure-activity relationships for human health effects: commonalities with other endpoints. Environ. Toxicol. Chem. 2003, 22:1829-1843.
13. De Graaf A., Vermeulen N.P.E., Feenstra A.F. Cytochrome P450 in silico: an integrative approach. J. Med. Chem. 2005, 48:2725-2755.
14. Dibb S. Swimming in a sea of estrogens, chemical hormone disrupters. Ecologist 1995, 25:27-31.
15. Ecker G.F., Chiba P. QSAR studies on drug transporters involved in toxicology. Computational Toxicology - Risk Assessment for Pharmaceutical and Environmental Chemicals 2007, 295-314. J. Wiley & Sons, New York, NY, USA. S. Ekins (Ed.).
16. Ekins S. Application of QSAR to enzymes involved in toxicology. Computational Toxicology - Risk Assessment for Pharmaceutical and Environmental Chemicals 2007, 277-294. J. Wiley & Sons, New York, NY, USA. S. Ekins (Ed.).
17. Enoch S.J., Cronin M.T.D., Schultz T.W., Madden J.C. Quantitative and mechanistic read across for predicting the skin sensitization potential of alkenes acting via Michael addition. Chem. Res. Toxicol. 2008, 21:513-520.
18. Fan E., Zhang L., Jiang S., Bai Y. Beneficial effects of resveratrol on arteriosclerosis. J. Med. Food 2008, 11:610-614.
19. Fischer B. Receptor-mediated effects of chlorinated hydrocarbons. Andrologia 2000, 32:279-283.
20. Green N., Naven R. Early toxicity screening strategies. Curr. Opin. Drug Discovery Dev. 2009, 12:90-97.
21. Guillette L.J., Crain D.A., Rooney A.A., Pickford D.B. Organization versus activation: the role of endocrine disrupting contaminants EDCs during embryonic development in wildlife. Environ. Heal. Perspect. 1995, 103(supplement 7):157-164.
22. Gustaffson J.A. Receptor-mediated toxicity. Toxicol. Lett. 1995, 135:465-470.
23. Harbone J.B. Twenty-five years of chemical ecology. Nat. Prot. Rep. 2001, 18:361-379.
24. Hartung T. Toxicology for the 21st century. Nature 2009, 460:208-212.
25. Helma C. In silico toxicology: the state-of-the-art and strategies to predict human health effects. Curr. Opin. Drug Discovery Dev. 2005, 8:27-31.
26. Hoffmann P., Warner B. Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends. J. Pharmacol. Toxicol. Methods 2006, 53:87-105.
27. Hopfinger A.J., Wang S., Tokarski J.S., Jin B., Albuquerque M., Madhav P.J., Duraiswami C. Construction of 3D-QSAR models using 4D-QSAR analysis formalism. J. Am. Chem. Soc. 1997, 119:10509-10524.
28. Humphrey W., Dalke A., Schulten K. VMD - visual molecular dynamics. J. Molec. Graphics 1996, 14.1:33-38.
29. Kavlock R.J., Ankley G., Blancato J., Breen M., Conolly R., Dix D., Houck K., Hubal E., Judson R., Rabinovitz J., Richard A., Setzer R.W., Shah I., Villeneuve D., Weber E. Computational toxicology - a state of the science mini review. Toxicology Sciences 2008, 103:14-27.
30. Lay K.M., Scrimshaw M.D., Lester J.N. The effect of natural and synthetic steroids in relation to their environmental occurrence. Crit. Rev. Toxicol. 2002, 32:113-132.
31. Lill M.A., Dobler M., Vedani A. Prediction of small-molecule binding to cytochrome P450 3A4: flexible docking combined with multidimensional QSAR. ChemMed Chem 2006, 1:73-81.
32. Lill M.A., Winiger F., Vedani A., Ernst B. Impact of induced fit on the ligand binding to the androgen receptor: a multidimensional QSAR study to predict endocrine-disrupting effects of environmental chemicals. J. Med. Chem. 2005, 48:5666-5674.
33. McLachlan J.A., Arnold S.F. Environmental estrogens. Am. Sci. 1996, 84:452-461.
34. Markus M.A., Morris B.J. Resveratrol in prevention and treatment of common clinical conditions of aging. Clin. Interv. Aging 2008, 3:331-339.
35. Merlot C. In silico methods for early toxicity assessment. Curr. Opin. Drug Discovery Dev. 2008, 11:80-85.
36. Muster W., Breidenbach A., Fischer H., Kirchner S., Müller L., Pähler A. Computational toxicology in drug development. Drug Discovery Today 2008, 13:303-310.
37. Nigsch F., Macaluso N.J.M., Mitchell J.B.O., Zmuidinavicus D. Computational toxicology: an overview of the sources of data and modelling methods. Expert Opin. Drug Metabol. Toxicol. 2009, 5:1-14.
38. Papa E., Villa F., Gramatica P. Statistically validated QSARs based on theoretical descriptors for modeling aquatic toxicity of organic chemicals in Pimephales promelas (fathead minnow). J. Chem. Inf. Model. 2005, 45:1256-1266.
39. Pavan M., Worth A. Publicly accessible QSAR software tools developed by the Joint Research Centre. SAR QSAR Environ. Res. 2008, 19:785-799.
40. Peristera O., Spreafico M., Smisko M., Ernst B., Vedani A. Mixed-model QSAR at the human mineralocorticoid receptor: predicting binding mode and affinity of anabolic steroids. Toxicol. Lett. 2009, 189:219-224.
41. Piclin N., Pintore M., Wechman C., Roncaglioni A., Benfenati E., Chretien J.R. Ecotoxicity prediction by adaptive fuzzy-partitioning: comparing descriptors computed on 2D and 3D structures. SAR QSAR Environ. Res. 2006, 17:225-251.
42. Rihova B. Receptor-mediated targeted drug or toxin delivery. Adv. Drug Deliv. Rev. 1998, 29:273-289.
43. Rocha-Gonzales H.I., Ambriz-Tututti M., Granados-Soto V. Resveratrol: a natural compound with pharmacological potential in neurodegenerative diseases. CNS Neurosci. Ther. 2008, 14:234-247.
44. Rossato G., Ernst B., Smiesko M., Spreafico M., Vedani A. Probing small-molecule binding to cytochrome P450 2D6 and 2C9: An in silico protocol for generating toxicity alerts. ChemMedChem 2010, 5:2088-2101.
45. Serafimova R., Todorov M., Pavlov T., Kotov S., Jacob E., Aptula A., Mekenyan O. Identification of the structural requirements of mutagenicity by incorporating molecular flexibility and metabolic activation of chemicals. II. General Ames mutagenicity model. Chem. Res. Toxicol. 2007, 20:662-676.
46. Simon-Hettich B., Rothfuss A., Steger-Hartmann T. Use of computer-assisted prediction of toxic effects of chemical substances. Toxicology 2006, 22:156-162.
47. Spreafico M., Smiesko M., Peristera O., Rossato G., Vedani A. Probing small-molecule binding to the liver-X receptor: a mixed-model QSAR study. Mol. Inf. 2010, 1:27-36.
48. Spreafico M., Smiesko M., Lill M.A., Ernst B., Vedani A. Mixed-model QSAR at the glucocorticoid receptor: predicting the binding mode and affinity of psychotropic drugs. ChemMedChem 2009, 4:100-109.
49. Taylor J.A., Richter C.A., Rahlen R.L., vom Saal F.S. Estrogenic environmental chemicals and drugs: mechanisms for effect on the developing male urogenital system. J. Steroid Biochem. Mol. Biol. 2011, 127:83-95.
50. Thorsteinson N., Ban F., Santos-Filho O., Tabaei S.M.H., Miguel-Queralt S., Underhill C., Cherkasov A., Hammond G.L. In silico identification of anthropogenic chemicals as ligands of zebrafish sex hormone binding globulin. Toxicol. Appl. Pharmacol. 2009, 234:47-57.
51. Valerio L.G. In silico toxicology for the pharmaceutical sciences. Toxicol. Appl. Pharmacol. 2009, 241:356-370.
52. Vedani, A. (2012): VirtualToxLab 4.2 documentation: VirtualToxLab. pdf. http://www.biograf.ch/downloads/.
53. Vedani A., Spreafico M., Peristera O., Smiesko M. VirtualToxLab - In silico prediction of the endocrine-disrupting potential of drugs and chemicals. Chimia 2008, 5:322-328.
54. Vedani A., Decloux A.V., Spreafico M., Ernst B. Predicting the toxic potential of drugs and chemicals in silico: a model for the peroxisome proliferator-activated receptor γ. Toxicol. Lett. 2007, 173:17-23.
55. Vedani A., Zumstein M., Lill M.A., Ernst B. Simulating α/β specificity at the thyroid receptor: consensus scoring in multidimensional QSAR. ChemMed Chem 2007, 2:78-87.
56. Vedani A., Dobler M., Lill M.A. The challenge of predicting drug toxicity in silico. Pharmacol. Toxicol. 2006, 99:195-208.
57. Vedani A., Dobler M., Lill M.A. Combining protein modeling and 6D-QSAR - simulating the binding of structurally diverse ligands to the estrogen receptor. J. Med. Chem. 2005, 48:3700-3703.
58. Vedani A., Dobler M. 5D-QSAR: the key for simulating induced fit?. J. Med. Chem. 2002, 45:2139-2149.
59. Vedani A., Briem H., Dobler M., Dollinger K., McMasters D.R. Multiple conformation and protonation-state representation in 4D-QSAR: the neurokinin-1 receptor system. J. Med. Chem. 2000, 43:4416-4427.
60. Vedani A., Huhta D.W. A new force field for modeling metalloproteins. J. Am. Chem. Soc. 1990, 112:4759-4767.
61. Vedani A., McMasters D.R., Dobler M. Genetic algorithms in 3D-QSAR: The use of multiple ligand orientations for improved prediction of toxicity. ALTEX 1999, 16:142-145.
62. Veith G.D. On the nature, evolution and future of quantitative structure-activity relationships (QSAR) in toxicology. SAR QSAR Environ. Res. 2004, 15:323-330.
63. Vingtdeux V., Dreses-Werringloer U., Zhao H., Davies P., Marambaud P. Therapeutic potential of resveratrol in Alzheimer's diseases. BMC Neurosci. 2008, 9(Suppl. 2):6.
64. Zvinavashe E., van den Berg H., Soffers A.E.M.F., Vervoort J., Freidig A., Murk A.J., Rietjens I.M.C.M. QSAR models for predicting in vivo aquatic toxicity of chlorinated alkanes to fish. Chem. Res. Toxicol. 2008, 21:739-745.